WALTHAM, Mass., May 28, 2024 /PRNewswire/ — Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that…